Skip to main content
SpringerLink
Log in

Clozapine: New research on efficacy and mechanism of action

  • Published:
European archives of psychiatry and neurological sciences Aims and scope Submit manuscript

Summary

Clozapine can produce greater clinical improvement in both positive and negative symptoms than typical antipsychotic drugs in neuroleptic-resistant schizophrenic patients. The clinical response may occur rapidly in some patients but is delayed in others. Clozapine has also been reported to produce fewer parkinsonian symptoms, to involve a lower risk of producing tardive dyskinesia, and to produce no serum prolactin elevations in man. It seems likely that these effects are the result of a common biological mechanism or related mechanisms, rather than unrelated effects. Other atypical antipsychotic drugs, such as melperone and fluperlapine, share at least some of these properties. A relatively low affinity for the D-2 dopamine (DA) receptor and high affinity for the 5-HT2 receptor, producing a high 5-HT2/D-2 ratio, best distinguishes atypical antipsychotics like clozapine from typical antipsychotic drugs. Through its weak antagonist action on D-2 DA receptors and a potent inhibitory effect on 5-HT2 receptors, as well as its abiltiy to increase DA and 5-HT release, clozapine may be able to permit more normal dopaminergic function in the anterior pituitary, the mesostriatal, mesolimbic and mesocortical regions. The numerous advantages of clozapine over typical neuroleptics are consistent with the primary importance of DA to the pathophysiology of schizophrenia. The secondary but still significant role of 5-HT in the action of clozapine may either be direct or via the effect of 5-HT on dopaminergic mechanisms. Some aspects of schizophrenia could be due to a dysregulation of the interaction between serotonergic and dopaminergic neurotransmission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Altar CA, Wasley DM, Neale RF, Stone GA (1986) Typical and atypical antipsychotic occupancy of D-2 and S-2 receptors: an autoradiographic study in rat brain. Brain Res Bull 16:527–525

    Google Scholar 

  • Altar CA, Wasley A, Gerhardt SC, Liebman GM, Wood PL (1988) Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists. NaunynSchmiedeberg's Arch Pharmacol 338:162–168

    Google Scholar 

  • Andersen PH, Braestrup C (1986) Evidence for different states of the dopamine D-1 receptor: clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of the D-1 receptor. J Neurochem 47:1822–1831

    Google Scholar 

  • Andersen PH, Nielsen EB, Gronvald FC, Braestrup C (1986) Some atypical neuroleptics inhibit [3H]SCH-23390 binding in vivo. Eur J Pharmacol 120:143–144

    Google Scholar 

  • Andevran D, Griffith RW (1977) Clozapine-induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol 11:1–3

    Google Scholar 

  • Angst J, Bente D, Berner P, Heimann H, Helmchen H, Hippius H (1971) Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-system). Pharmakopsychiatrie 4:200–211

    Google Scholar 

  • Beaulieu M (1987) Clinical importance of D-1 and D-2 receptors. Can J Neurol Sci 14:402–406

    Google Scholar 

  • Bersani G, Grispini A, Morini S, Pasini A, Valducci M, Ciani A (1986) Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 40:492–499

    Google Scholar 

  • Bischoff S (1986) Mesohippocampal dopamine system: characterization, functional and clinical implications. In: Issacson RL, Pribram KH (eds) The hippocampus, vol 3. Plenum, New York, pp 1–32

    Google Scholar 

  • Bjerkenstedt L, Gullberg B, Härnryd C, Sedvall G (1979) Relationships between clinical and biochemical effects of melperone and thiothixene in psychotic women. Arch Psychiatr Nervenkr 227:181–192

    Google Scholar 

  • Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179–186

    Google Scholar 

  • Ceulemans DLS (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 85:329–332

    Google Scholar 

  • Chen J-C, Ramirez VD (1988) In vivo dopaminergic activity from nucleus accumbens, substantia nigra and ventral tegemental area in the freely-moving rat: basal neurochemical output and porlactin effect. Neuroendocrinology 48:329–335

    Google Scholar 

  • Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration of the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607–1619

    Google Scholar 

  • Chiodo LA, Bunney BS (1985) Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain and dopamine neurons. J Neurosci 5:2539–2544

    Google Scholar 

  • Christensen I, Gustafsson B (1985) Amperozide, a novel psychotropic compound with specific effect on limbic brain areas. Acta Physiol Scand 124 [Suppl 542]:281

    Google Scholar 

  • Christensen I, Geisman L, Kirkegaard A, Kirkegarrd G (1986) Additional studies on side effects of melperone in long-term therapy for 1-20 years in psychiatric patients. Arzneimittelforschung 36:855–860

    Google Scholar 

  • Claghorn JL, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, Klerman GL (1987) The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7:377–384

    Google Scholar 

  • Clark D, White FI (1988) Dopamine receptor - the search for a function: a critical evaluation of the D-1/D-2 dopamine receptor classification and its functional implications. Synapse 1:347–388

    Google Scholar 

  • Costall B, Fortune DH, Naylor BJ, Marsden CD, Pycock CJ (1975) Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 14:859–868

    Google Scholar 

  • Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process. Br Med J 280:66–68

    Google Scholar 

  • Dieterle D, Eben E, Einhaupi K, Hippius H, Klein H, Rüther E, Schmauss M (1984) The effect of fluperlapine in acute psychotic patients. Pharmacopsychiatry 7:57–60

    Google Scholar 

  • Donaldson SG, Gelenberg AJ, Baldessarini RJ (1985) The pharmacologic treatment of schizophrenia: a progress report. Schizophr Bull 11:5–28

    Google Scholar 

  • Dray A (1981) Serotonin and the basal ganglia; functions and interactions with other neuronal pathways. J Physiol (Paris) 77:393–403

    Google Scholar 

  • Drescher K, Hetey L (1988) Influence of antipsychotics and serotonin antagonists on presynaptic receptors modulating the release of serotonin in synaptosomes of the nucleus accumbens of rats. Neuropharmacology 27:31–36

    Google Scholar 

  • Fink H, Morgenstern R, Oelssner W (1984) Clozapine — a serotonin antagonist? Pharmacol Biochem Behav 20:513–517

    Google Scholar 

  • Fischer-Cornellssen KA (1984) Fluperlapine in 104 schizophrenic patients. Open multicenter trial. Arzneimittelforschung 34:125–130

    Google Scholar 

  • Fischer-Comellssen KA, Ferner U (1976) An example European multicenter trials; multispectral analysis of clozapine. Psychopharmacol Bull 12:34–39

    Google Scholar 

  • Friedhoff AJ (1988) Dopamine as a mediator of a central stabilizing system. Neuropsychopharmacology 1:189–191

    Google Scholar 

  • Gerlach J, Korsgaard S, Noring U (1984) Primary (initial) and secondary (tardive) dyskinesia: effect of fluperlapine, a new typical neuroleptic drug. In: Usdin E, Carlsson A, Dahlstrom A, Engel J (eds) Catecholamines, part C: neuropharmacology and central nervous system — therapeutic aspects. Liss, New York, pp 73–78

    Google Scholar 

  • Goldstein JM, Litwin LC, Sutton EB, Malick JB (1987) D-2 dopamine antagonist-like effect of SCH-23390 on A9 and A10 dopamine neurons. Life Sci 40:1039–1044

    Google Scholar 

  • Gudelsky GA, Meltzer HY (1989) Activation of tuberoinfundibular neurons following the acute administration of atypical antipsychotics. Neuropsychopharmacology 2:45–51

    Google Scholar 

  • Gudelsky GA, Koenig JI, Simonovic M, Koyama T, Ohmori T, Meltzer HY (1987) Differential effects of haloperidol, clozapine, and fluperlapine on tubero-in-fundibular dopamine neurons and prolactin secretion in the rat. J Neural Transm 68:227–240

    Google Scholar 

  • Heinrichs DW, Hanlow ET, Carpenter WT Jr (1984) The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10:388–396

    Google Scholar 

  • Here D, Simon H, Blanc G, Lisoprawski A, LeMoal M, Glowinski J, Tassin JP (1979) Increased utilization of dopamine in the nucleus accumbens but not in the cerebral cortex after dorsal raphe lesion in the rat. Neurosci Lett 15:127–134

    Google Scholar 

  • Hervé D, Simon H, Blanc G, LeMoal M, Glowinski J, Tassin JP (1981) Opposite changes in dopamine utilization in the nucleus accumbens and the frontal cortex after electrolytic lesion of the median raphe in the rat. Brain Res 216:422–428

    Google Scholar 

  • Hess EJ, Bracha HS, Kleinman JE, Creese I (1987) Dopamine receptor subtype imbalance in schizophrenia. Life Sci 40:1487–1497

    Google Scholar 

  • Hruska RE (1986) Modulation role for prolactin in the elevation of striatal dopamine receptor density induced by chronic treatment with dopamine receptor antagonist. Brain Res Bull 16:331–339

    Google Scholar 

  • Imperato A, Angelucci L (1988) Effects of the atypical neuroleptics, clozapine and fluperlapine on the in vivo dopamine release in the dorsal striatum and in the prefrontal cortex. Abstracts of the XVI CINP Congress, Munich. Psychopharmacology 96 [Suppl 1]:79

    Google Scholar 

  • Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH-23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226:462–468

    Google Scholar 

  • Juul-Povlsen U, Noring J, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 71:176–185

    Google Scholar 

  • Kane JM (1987) Treatment of schizophrenia. Schizophr Bull, pp 133–156

  • Kane JM, Woerner M, Borenstein M, Wegner J, Liberman J (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254–258

    Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer HY, the Clozaril Collaborative Study Group (1988) Clozapine for the treatmentresistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796

    Google Scholar 

  • Koenig JI, Gudelsky GA, Meltzer HY (1987) Stimulation of corticosterone and ß-endorphin secretion in the rat by selective 5-HT receptor subtype activation. Eur J Pharmacol 137:1–8

    Google Scholar 

  • Kovacs GL, Drago F, Acasi L, Tihanyi A, Scapagnini V, Telegdy G (1984) Catecholamine utilization in specific rat brain nuclei after short-term hyperprolactinemia. Brain Res 324:29–34

    Google Scholar 

  • Lee T, Seeman P (1980) Elevation of brain neuroleptic/dopamine receptors in schizophrenia. Am J Psychiatry 137:191–197

    Google Scholar 

  • Lindstrom LH (1988) The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 77:524–529

    Google Scholar 

  • Lowy MT, Koenig JI, Meltzer HY (1988) Stimulation of serum cortisol and prolactin in man by MK-212, a centrally active serotonin agonist. Biol Psychiatry 23:818–828

    Google Scholar 

  • MacKay AVP (1980) Positive and negative symptoms and the role of dopamine. Br J Psychiatry 137:379–383

    Google Scholar 

  • Matsubara S, Meltzer HY (1988) Effect of typical and atypical antipsychotic drugs on D-1 and D-2 dopamine (DA) receptor and serotonin (5-HTZ) receptors. Neurosci Abs 14:370

    Google Scholar 

  • Matsubara S, Meltzer HY (1988) Effect of typical and atypical antipsychotic drugs on 5-HTZ receptor density in rat cerebral cortex. Life Sci (in press)

  • Matz R, Rick W, Oh D, Thompson H, Gershon S (1974) Clozapine — a potential antipsychotic agent without extrapyramidal manifestation. Curr Ther Res 16:687–695

    Google Scholar 

  • Mefford IN, Roth KA, Agren H, Barchas JD (1988) Enhancement of dopamine metabolism in rat brain frontal cortex: a common effect of chronically administered antipsychotic drugs. Brain Res 475:380–384

    Google Scholar 

  • Meltzer HY (1982) Dopamine autoreceptor stimulation: clinical significance. Pharmacol Biochem Behav 17:1–10

    Google Scholar 

  • Meltzer HY (1984) Biological studies in schizophrenia. Schiz Bull 13:77–114

    Google Scholar 

  • Meltzer HY (1985) Dopamine and negative symptoms in schizophrenia: critique of the Type I-Type II hypothesis. In: Alpert M (ed) Controversies in schizophrenia: changes and constancies. Guilford Press, New York, pp 110–136

    Google Scholar 

  • Meltzer HY (1986) Novel approaches to the pharmacotherapy of schizophrenia. Drug Develop Res 9:23–40

    Google Scholar 

  • Meltzer HY (1987) Biological studies in Schizophrenia. Schizophr Bull Rep 3:72–114

    Google Scholar 

  • Meltzer HY (1988) New insights into schizophrenia through atypical antipsychotic drugs: Comments on “The current status of the dopamine hypothesis of schizophrenia”. Neuropsychopharmacology 1:193–196

    Google Scholar 

  • Meltzer HY (1989a) Clozapine: clinical advantages and biological mechanisms. In: Schulz C, Tamminga C (eds) Schizophrenia: A Scientific Focus. International Conference on Schizophrenia. Oxford Press, New York, pp 302–309

    Google Scholar 

  • Meltzer HY (1989b) Clinical studies on the mechanism of action of clozapine: The dopamine serotonin hypothesis of schizophrenia. Psychopharmacol (in press)

  • Meltzer HY (1989c) Clozapine: Mechanism of action in relation to its clinical advantages. In: Kales A, Stefanos CN, Talbott J (eds) Recent advances in schizophrenia. (In press)

  • Meltzer HY, Luchins DJ (1984) Effect of clozapine in severe tardive dyskinesia: a case report. J Clin Psychopharmacol 4:316–322

    Google Scholar 

  • Meltzer HY, Stahl S (1976) The dopamine hypothesis: a review. Schizophr Bull 2:19–76

    Google Scholar 

  • Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS (1979) Effect of clozapine on human serum prolactin levels. Am J Psychiatry 136:1550–1555

    Google Scholar 

  • Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC (1979) Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Trans 45:165–175

    Google Scholar 

  • Meltzer HY, Nash JF, Koenig JI, Gudelsky GA (1986a) Clozapine: neuroendocrine studies of an atypical neuroleptic. Clin Neuropharmacol 9:316–318

    Google Scholar 

  • Meltzer HY, Sommers AA, Luchins DJ (1986b) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 6:329–338

    Google Scholar 

  • Meltzer HY, Bastani B, Kwon K, Young, Ramirez L, Burnett S, Sharpe J (1989a) A prospective study of clozapine in treatment-resistant schizophrenia patients. I. Preliminary report. Psychopharmacology (in press)

  • Meltzer HY, Matsubara S, Lee J-C (1989b) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther (in press)

  • Memo M, Kleirman JE, Hanbauer I (1983) Coupling of dopamine D1 recognition sites with adenlyate cyclase in nuclei accumbens and caudatus of schizophrenics. Science 221:1302–1304

    Google Scholar 

  • Morelli M, Fenu S, Di Chiara G (1987) Behavioral expression of D-1 receptor supersensitivity depends on previous stimulation of D-2 receptors. Life Sci 40:245–251

    Google Scholar 

  • Nash JF, Meltzer HY, Gudelsky GA (1988) Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. Eur J Pharmacol 151:463–469

    Google Scholar 

  • Nicolaou NM, Garcia-Mufloz M, Arbuthnott GW, Eccleston D (1979) Interactions between serotonergic and dopaminergic systems in rat brain demonstrated by small unilateral lesions of the raphé nuclei. Eur J Pharmacol 57:295–305

    Google Scholar 

  • Overall JE, Gorham DR (1962) Brief Psychiatric Rating Scale (BPRS). Psychol Rep 10:799–812

    Google Scholar 

  • Owen F, Cross AJ, Crow TJ, Longden A, Poulter M, Riley GJ (1978) Increased dopamine receptor sensitivity in schizophrenia. Lancet II:223–226

    Google Scholar 

  • Pugh MT, O'Boyle KM, Molloy AG, Waddington JL (1985) Effects of the putative D-1 antagonist SCH-23390 on stereotyped behavior induced by the D-2 agonist RU-24213. Psychopharmacology 87:308–312

    Google Scholar 

  • Reynolds GP, Garrett NJ, Rupniak N, Jenner P, Marsden CD (1983) Chronic clozapine treatment of rats down-regulates cortical 5-HTZ receptors. Eur J Pharmacol 89:325–326

    Google Scholar 

  • Ruch W, Asper H, Bürke HR (1976) Psychopharmacology (Berlin) 46:103–109

    Google Scholar 

  • Rupniak NML, Hall MD, Mann S, Fleminger S, Kilpatrick G, Jenner P, Marsden CD (1985) Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem Pharmacol 34:2755–2763

    Google Scholar 

  • Saller CF, Salama AI (1986) D-1 and D-2 dopamine receptor blockade: interactive effects in vitro and in vivo. J Pharmacol Exp Ther 236:714–720

    Google Scholar 

  • Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clopazine and fluperlapine. Eur Arch Psychiatry Neurol Sci 235:60–64

    Google Scholar 

  • Simpson GM, Lee JH, Shrivastava RK (1978) Clozapine in tardive dyskinesia. Psychopharmacology 56:75–80

    Google Scholar 

  • Snyder SH (1976) The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 133:197–202

    Google Scholar 

  • Stoof JC, Verheijden PFHM (1986) D-2 receptor stimulation inhibits cyclic AMP formation brought about by D-1 receptor stimulation in rat neostriatum but not nucleus accumbens. Eur J Pharmacol 129:205–206

    Google Scholar 

  • Sulpizio A, Fowler PJ, Macko E (1978) Antagonism of fenfluramine-induced hyperthermia: a measure of central serotonin inhibition. Life Sci 22:1439–1446

    Google Scholar 

  • Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kurumaji A, Takashima M, Mataga N, Ogawa A (1988) Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78:121–137

    Google Scholar 

  • Waldmeier PS, Delini-Stula AA (1979) Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 55:363–373

    Google Scholar 

  • Woggon B, Heinrich K, Kufferle B, Müller-Oerlinghausen B, Poldinger W, Rüther E, Schied HW (1985) Fluperlapine — a potential successor to clozapine. Pharmacopsychiatry 18:73–74

    Google Scholar 

  • Young MA, Meltzer HY (1980) RMI-81,582, a novel antipsychotic drug. Psychopharmacology 67:101–106

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Case Western Reserve University, School of Medicine, 2040 Abington Road, 1441, Cleveland, OH, USA

    Herbert Y. Meltzer, Bijan Bastani, Luis Ramirez & Shigehiro Matsubara

Authors
  1. Herbert Y. Meltzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bijan Bastani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luis Ramirez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shigehiro Matsubara
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Parts of this article were presented on the occasion of the inauguration ceremony of the Department of Psychiatry of the University of Mainz on April 2 and 3, 1987

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meltzer, H.Y., Bastani, B., Ramirez, L. et al. Clozapine: New research on efficacy and mechanism of action. Eur Arch Psychiatr Neurol Sci 238, 332–339 (1989). https://doi.org/10.1007/BF00449814

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00449814

Key words

Search

Navigation